pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
onclive·May 7·1 min read
save

EGFR-Targeted Therapy Sequencing After Resistance in NSCLC

May 7, 2026·read at onclive ↗

Learn how clinicians tackle EGFR lung cancer resistance—using NGS, radiation, chemo, amivantamab, and ADCs to tailor next-line therapy.

source

Reporting by onclive.

read at onclive ↗
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

drugs
amivantamab
topics
EGFR2NSCLC2OncologyPulmonology

related stories

  • Aug 13New Taiho, Cullinan data heats up lung cancer drug battleBioPharma Dive
  • Aug 13Taiho and Cullinan’s zipalertinib clears Phase 3, teeing up first-line competitionBioSpace
  • Aug 13Taiho, Cullinan's lung cancer drug passes Phase 3 test, lining up Rybrevant contestEndpoints
  • Aug 13Cullinan tees up J&J fight—and $100M payday—as Taiho-partnered drug hits phase 3 cancer goalFierce Biotech
  • Aug 7BlossomHill, Latigo outshine IPO expectations with oversubscribed debutsFierce Biotech